{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-006803","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.757204+00:00","generated_at":"2026-06-23T04:38:15.031543+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PharmaCyte CEO resigns; interim CEO appointed; Board forms Business Review Committee to evaluate strategic options","bullets":["CEO Kenneth Waggoner resigned effective Oct 6; separation agreement provides $216,667 lump sum and $433,333 consulting payments over 12 months.","Board appointed Joshua Silverman as interim CEO and Chairman; Silverman is a director since Aug 2022 and co-founder of Parkfield Funding.","Board's Business Review Committee to evaluate opportunities including FDA clinical hold on Cell-in-a-Box IND and relationship with SG Austria.","Company continuing share repurchase program of up to $10 million; spending on programs curtailed pending review."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-006803","json":"https://secwatch.observer/filing/0001683168-22-006803.json","markdown":"https://secwatch.observer/filing/0001683168-22-006803.md","text":"https://secwatch.observer/filing/0001683168-22-006803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:38:15.031543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a945a02d55","claim":"Joshua N. Silverman was appointed as interim Chairman of the Board, interim Chief Executive Officer and interim President at PharmaCyte Biotech, Inc..","evidence_excerpt":"Effective October 6, 2022, the Board appointed Joshua N. Silverman, a director on the Board since August 2022, as interim Chairman of the Board, interim Chief Executive Officer and interim President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chairman of the Board, interim Chief Executive Officer and interim President"}],"fact_type":"executive_change"},{"claim_id":"f3e8672ac6","claim":"Kenneth L. Waggoner resigned as Chief Executive Officer, President and General Counsel at PharmaCyte Biotech, Inc..","evidence_excerpt":"Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech , Inc. ( the “Company”) resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the “Company Group”) and as a director on the Board of Directors of the Company (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer, President and General Counsel"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}